/
We are a fully integrated, global, commercial-stage biotechnology company focused on the discovery, development, manufacturing and commercialization of genetic medicines to treat diseases with high unmet medical needs. Using our patented gene therapy technology platform that is based on engineered herpes simplex virus-1 ( HSV-1 ), we create vectors that efficiently deliver therapeutic …
41.45% operating margin is above average. ROIC at 11.68%.
Revenue up 33.9% YoY with margins expanding 18.8pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$417M
▲ +33.9% YoY
Net Income (TTM)
$225M
▲ +129.7% YoY
Op. Margin
42.83%
▲ +18.8pp YoY
ROIC
11.99%
▲ +4.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$237M
▲ +58.5% YoY
Op. Cash Flow (TTM)
$250M
▲ +62.7% YoY
Net Debt
-$814M
Net Cash Position
Cash & Equiv.
$823M
Continue Research